Jon Faiz Kayyem, SVP, Research & Development at GenMark Diagnostics, Inc. (GNMK), sold 148 shares at $5.13 ($759) on 2018-02-02, disclosed to the SEC on 2018-02-06.
Seasonal sale ($759) by SVP, Research & Development — this insider has traded GNMK in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| INBX | BUY | 2026-09-08 | $568K | — | Filing → |
| INBX | BUY | 2024-11-22 | $1.5M | — | Filing → |
| INBX | BUY | 2024-06-07 | $2.0M | — | Filing → |